ZA9810130B - Tumor-specific antigens methods for their production and their use for imunization and diagnosis - Google Patents

Tumor-specific antigens methods for their production and their use for imunization and diagnosis

Info

Publication number
ZA9810130B
ZA9810130B ZA9810130A ZA9810130A ZA9810130B ZA 9810130 B ZA9810130 B ZA 9810130B ZA 9810130 A ZA9810130 A ZA 9810130A ZA 9810130 A ZA9810130 A ZA 9810130A ZA 9810130 B ZA9810130 B ZA 9810130B
Authority
ZA
South Africa
Prior art keywords
imunization
tumor
diagnosis
production
specific antigens
Prior art date
Application number
ZA9810130A
Inventor
Andrea Anichini
Giorgio Parmiani
Marialuisa Sensi
Catia Traversari
Original Assignee
Boehringer Mannheim Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim Gmbh filed Critical Boehringer Mannheim Gmbh
Publication of ZA9810130B publication Critical patent/ZA9810130B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Plant Pathology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA9810130A 1997-11-06 1998-11-05 Tumor-specific antigens methods for their production and their use for imunization and diagnosis ZA9810130B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP97119404 1997-11-06

Publications (1)

Publication Number Publication Date
ZA9810130B true ZA9810130B (en) 1999-05-06

Family

ID=8227582

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9810130A ZA9810130B (en) 1997-11-06 1998-11-05 Tumor-specific antigens methods for their production and their use for imunization and diagnosis

Country Status (11)

Country Link
EP (1) EP1029050A1 (en)
JP (1) JP2001522603A (en)
KR (1) KR20010024585A (en)
CN (1) CN1278865A (en)
AR (1) AR017562A1 (en)
AU (1) AU743066B2 (en)
BR (1) BR9813981A (en)
CA (1) CA2309557A1 (en)
TR (1) TR200001253T2 (en)
WO (1) WO1999024566A1 (en)
ZA (1) ZA9810130B (en)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (en) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Recombinant vaccines and their use
DE102005046490A1 (en) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency
ES2746233T3 (en) 2011-05-24 2020-03-05 Biontech Rna Pharmaceuticals Gmbh Individualized vaccines for cancer
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
EP3194970B1 (en) 2014-09-10 2021-07-28 F. Hoffmann-La Roche AG Immunogenic mutant peptide screening platform
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
JP2018517415A (en) 2015-06-10 2018-07-05 ナントクエスト インコーポレイテッド Modified NK-92 cells for treating cancer
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
KR102414519B1 (en) * 2016-03-03 2022-06-28 인스티튜트 구스타브 루시 PTPS-based anti-cancer vaccine
JP2019532640A (en) 2016-09-29 2019-11-14 ナントクエスト インコーポレイテッド HLA class I deficient NK-92 cells with reduced immunogenicity
KR102528384B1 (en) 2017-01-06 2023-05-02 이뮤너티바이오, 인크. Genetically Modified NK-92 Cells with Reduced CD96/TIGIT Expression
US20210187024A1 (en) 2017-11-01 2021-06-24 Nantkwest, Inc. NK-92 Cells to Stimulate Anti-Cancer Vaccine
DE112019000608B4 (en) 2018-01-31 2021-05-06 Nantkwest, Inc. USE OF 5% HUMAN ALBUMIN IN WASHING AND HARVESTING MEDIA
WO2019177986A1 (en) 2018-03-12 2019-09-19 Nantkwest, Inc. Use of cd33car modified high affinity nk cells (t-hank) to reduce myeloid-derived suppressor cells suppressor activity (or reduce negative impact on nk cell activity)
US20210198342A1 (en) 2018-05-22 2021-07-01 Nantkwest, Inc. FC-EPSILON CAR (Very imp commercially - in clinical trial)
AU2019274392A1 (en) 2018-05-22 2020-11-05 Nantkwest, Inc. Basal media for growing NK-92 cells
WO2019226649A1 (en) 2018-05-22 2019-11-28 Nantkwest, Inc. Optimization of nk-92 cell growth using poloxamer
US20210267190A1 (en) 2018-07-10 2021-09-02 Nantkwest, Inc. Cryopreservation
CN112424343A (en) 2018-07-10 2021-02-26 南克维斯特公司 Production of CIK NKT cells from umbilical cord blood
US20210293787A1 (en) 2018-08-01 2021-09-23 Nantkwest, Inc. Combined invasion and cytotoxicity assay using chemokine secreting target cells
JP7241161B2 (en) 2018-08-01 2023-03-16 イミュニティーバイオ、インコーポレイテッド A quadricistronic system comprising homing receptors or cytokines and chimeric antigen receptors for stable genetic modification of cellular immunotherapy
EP3830113A1 (en) 2018-08-01 2021-06-09 Nantkwest, Inc. Chemokine responsive activated natural killer cells with secondary homing activation for verified targets
JP2022533806A (en) 2018-11-06 2022-07-26 イミュニティーバイオ、インコーポレイテッド NK-92 cells modified with chimeric antigen receptors
CN113164521A (en) 2018-11-26 2021-07-23 免疫生物公司 IL-2 dependent NK-92 cells with stable Fc receptor expression
CN110491450B (en) * 2019-08-23 2023-05-16 深圳市新合生物医疗科技有限公司 Tumor neogenesis antigen prediction platform and application thereof
US11230699B2 (en) 2020-01-28 2022-01-25 Immunitybio, Inc. Chimeric antigen receptor-modified NK-92 cells targeting EGFR super-family receptors
WO2023081163A1 (en) 2021-11-02 2023-05-11 Immunitybio, Inc. Natural killer cells for chordoma therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein

Also Published As

Publication number Publication date
JP2001522603A (en) 2001-11-20
AR017562A1 (en) 2001-09-12
EP1029050A1 (en) 2000-08-23
WO1999024566A1 (en) 1999-05-20
AU2151899A (en) 1999-05-31
TR200001253T2 (en) 2000-11-21
AU743066B2 (en) 2002-01-17
CA2309557A1 (en) 1999-05-20
CN1278865A (en) 2001-01-03
BR9813981A (en) 2000-09-26
KR20010024585A (en) 2001-03-26

Similar Documents

Publication Publication Date Title
ZA9810130B (en) Tumor-specific antigens methods for their production and their use for imunization and diagnosis
IL126811A0 (en) Human b-cell antigens and related reagents
PL330111A1 (en) Concentyratyed antibody preparation
ZA959336B (en) Antibodies
AU1704099A (en) Monoclonal human natural antibodies
HUP0104774A3 (en) Streptococcus antigens
EP1039834A4 (en) Optoacoustic contrast agents and methods for their use
AU6266899A (en) Methods for producing human tumor antigen specific antibodies
IL136308A0 (en) Antipicornaviral compounds and methods for their use and preparation
NZ279605A (en) T-cell antigen receptor v region production and use
AU7180198A (en) Human breast tumor-specific proteins
HUP0000318A3 (en) Tumor vaccine and process for the preparation thereof
GB9806666D0 (en) Antigen preparation and use
ZA962280B (en) RAGE tumor rejection antigens
AU7676300A (en) Human anti-adipocyte monoclonal antibodies and their use
HU9802132D0 (en) Biphenyl-sulfonyl-cyanamides, process for producing them and their medical use
HUP9800744A3 (en) Antibodies against fas-antigene
GB9714971D0 (en) Assays,therapeutic methods and means
EP0977590A4 (en) Human monoclonal antibodies
EP0888126A4 (en) Anti-idiotypic antibody vaccines
CZ20011896A3 (en) Immunogenic preparation and antibody
ZA941645B (en) Antibodies specifically reactive against human prostate specific antigen.
AU1135595A (en) Saccharomyces-specific antigens and antibodies, their preparation and use
AU3753499A (en) Colon cancer-associated antigens and their diagnostic and therapeutic uses
GB9726147D0 (en) Antigens